Mice treated with rimonabant show the same resistance to hepatic steatosis, insulin resistance, dyslipidemia, and obesity as do mice lacking Cnr1 (19, 20, 42, 43, 46, 48) or Dagla (data presented here), suggesting that Dagla inhibitors may achieve the same effects as Cnr1 inverse agonists if delivered to the right location. This evidence concerns the gene DAGLA and fatty liver disease.